Compare
MagDI vs GLP-1 Medications
GLP-1 receptor agonists (semaglutide, tirzepatide, and related medications) have transformed pharmacologic treatment of obesity and Type 2 Diabetes. MagDI is a procedural option that creates a duodeno-ileal anastomosis. They are not mutually exclusive.
Written by MagnaMetabolic Editorial Team Medically reviewed by Ariel Ortiz, MD — Bariatric & Metabolic Surgery Last reviewed: June 7, 2026
Type of intervention
- GLP-1 medications: long-term pharmacotherapy; effect generally diminishes if the medication is discontinued.
- MagDI: procedural intervention creating an anatomical change intended to provide durable effect.
Considerations
- Many patients use GLP-1 medications and procedural treatments at different points in their care.
- Cost, access, tolerability, comorbid conditions, and patient preference all factor into choice.
- Long-term comparative outcomes between MagDI and GLP-1 therapy are not yet established.
Decisions should be individualized in coordination with the patient's medical and surgical team.
Evidence
Scientific References
Selected primary sources informing this page. External links open in a new tab; we do not control or endorse third-party content.
- ADAAmerican Diabetes Association — Standards of Care in Diabetes (current edition), Section on obesity and metabolic surgery.
- ASMBSAmerican Society for Metabolic and Bariatric Surgery (ASMBS) and IFSO 2022 indications for metabolic and bariatric surgery.
- Obesity SurgeryGagner M, et al. First-in-human experience of magnetic duodeno-ileostomy for the treatment of obesity and metabolic disease. Obesity Surgery.
- Surgical EndoscopyMulti-center early outcomes of sleeve gastrectomy combined with magnetic duodeno-ileostomy (Sleeve Plus MagDI). Surgical Endoscopy.